MORE US FUNDS FOR STARPHARMA HIV/HERPES TRIALS
February 13th 2007 07:47
Biotech Daily Market Report Tuesday February 13, 2007
TODAY’S NEWS
* NEUREN’S NNZ-2566 REDUCES RAT BRAIN INJURY
* AGENIX DVT THROMBOVIEW STUDY ‘HIGHLY PROMISING’
* MORE US FUNDS FOR STARPHARMA HIV/HERPES TRIALS
* PRIMA DEAL EXPANDS CANCER TREATMENT POTENTIAL TO $2.5bn
* COCHLEAR H1 PROFITS UP 12% TO $48.8m
* CIRCADIAN H1 TURNAROUND PROFITS UP TO $9.1m
To view these articels readeers must subscribe to Biotech Daily
Go to www.biotechdaily.com.au
BIOTECHS UP 11% IN JANUARY, ALL ORDS UP 2.02%
The biotechnology sector continued to outstrip the All Ordinaries in January, with the Biotech Daily Top 40 Index up 11.3 percent to $5,292 million compared to the All Ordinaries up 2.02 percent.
The Top 20 climbed 11.8 percent for the month to $3,739 million with the Second 20 up 9.99 percent to $1,553 million.
For the 11 months from March 1, 2006 the Biotech Daily Top 40 was up 33.5 percent compared to the All Ordinaries up 18.4 percent.
ASX UP, BIOTECHS DOWN:
AGENIX UP 16%, CYGENICS DOWN 9%
AGENIX UP 16%, CYGENICS DOWN 9%
TODAY’S NEWS
* NEUREN’S NNZ-2566 REDUCES RAT BRAIN INJURY
* AGENIX DVT THROMBOVIEW STUDY ‘HIGHLY PROMISING’
* MORE US FUNDS FOR STARPHARMA HIV/HERPES TRIALS
* PRIMA DEAL EXPANDS CANCER TREATMENT POTENTIAL TO $2.5bn
* COCHLEAR H1 PROFITS UP 12% TO $48.8m
* CIRCADIAN H1 TURNAROUND PROFITS UP TO $9.1m
To view these articels readeers must subscribe to Biotech Daily
Go to www.biotechdaily.com.au
BIOTECHS UP 11% IN JANUARY, ALL ORDS UP 2.02%
The biotechnology sector continued to outstrip the All Ordinaries in January, with the Biotech Daily Top 40 Index up 11.3 percent to $5,292 million compared to the All Ordinaries up 2.02 percent.
The Top 20 climbed 11.8 percent for the month to $3,739 million with the Second 20 up 9.99 percent to $1,553 million.
For the 11 months from March 1, 2006 the Biotech Daily Top 40 was up 33.5 percent compared to the All Ordinaries up 18.4 percent.
| 49 |
| Vote |
Add To: 
subscribe to this blog